S Sivasubbu, V Scaria - Human genomics, 2019 - Springer
Home to a culturally heterogeneous population, India is also a melting pot of genetic diversity. The population architecture characterized by multiple endogamous groups with …
Both safety and efficacy of medical treatment can vary depending on the ethnogeographic background of the patient. One of the reasons underlying this variability is differences in …
C White, RJ Scott, C Paul, A Ziolkowski… - Clinical …, 2022 - Wiley Online Library
Fluoropyrimidines (FP; 5‐fluorouracil, capecitabine, and tegafur) are a commonly prescribed class of antimetabolite chemotherapies, used for various solid organ malignancies in over 2 …
C White, RJ Scott, C Paul, A Ziolkowski… - Pharmacogenomics …, 2021 - Taylor & Francis
Pharmacogenomic screening can identify patients with gene variants that predispose them to the development of severe toxicity from fluoropyrimidine (FP) chemotherapy. Deficiency of …
Fluorouracil, or 5-flourouracil (5-FU), is a chemotherapy agent that belongs to the drug class of fluoropyrimidines. When given as an intravenous (IV) solution, 5-FU is used in the …
While genomic approaches to precision medicine hold great promise, they remain prohibitively expensive for developing countries. The precision public health paradigm …
T Ahsan, NJ Urmi, AA Sajib - PLoS One, 2020 - journals.plos.org
Interethnic variability in drug response arises from genetic differences associated with drug metabolism, action and transport. These genetic variations can affect drug efficacy as well as …
E Zomawia, Z Zami, A Vanlallawma… - The Lancet Regional …, 2023 - thelancet.com
Background Despite being the second least populated state, Mizoram exhibits the highest incidence rate of cancer in India. Its inhabitants, constituting an endogamous and isolated …
S Fotheringham, GA Mozolowski… - Gastroenterology …, 2019 - academic.oup.com
Colorectal cancer remains one of the most common cancers worldwide and, despite improvements in treatment options for late-stage metastatic cancer, there are still questions …